Daehan New Pharm Co. Ltd (054670) — Capital Reinvestment Ratio
Daehan New Pharm Co. Ltd (054670) has a Capital Reinvestment Ratio of 2.61x as of September 2025, meaning it reinvests 3% of its operating cash flow (₩4.43 Billion) in capital expenditures (₩11.53 Billion). Check 054670 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Daehan New Pharm Co. Ltd Capital Reinvestment Ratio (2011–2024)
This chart tracks Daehan New Pharm Co. Ltd's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see Daehan New Pharm Co. Ltd operating cash flow efficiency.
Annual Capital Reinvestment Ratio for Daehan New Pharm Co. Ltd (2011–2024)
Year-by-year Capital Reinvestment Ratio for Daehan New Pharm Co. Ltd from 2011 to 2024. See 054670 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.81x | ₩18.95 Billion | ₩34.26 Billion | ▲ +128.8% |
| 2023 | 0.79x | ₩12.57 Billion | ₩9.93 Billion | ▲ +220.5% |
| 2022 | 0.25x | ₩14.25 Billion | ₩3.51 Billion | ▼ -61.3% |
| 2021 | 0.64x | ₩16.58 Billion | ₩10.55 Billion | ▼ -8.9% |
| 2020 | 0.70x | ₩13.55 Billion | ₩9.46 Billion | ▲ +76.2% |
| 2019 | 0.40x | ₩22.89 Billion | ₩9.08 Billion | ▲ +368.9% |
| 2018 | 0.08x | ₩20.47 Billion | ₩1.73 Billion | ▼ -83.8% |
| 2016 | 0.52x | ₩8.75 Billion | ₩4.57 Billion | ▲ +5.5% |
| 2015 | 0.50x | ₩7.80 Billion | ₩3.86 Billion | ▼ -25.9% |
| 2014 | 0.67x | ₩10.02 Billion | ₩6.69 Billion | ▼ -86.2% |
| 2012 | 4.83x | ₩256.82 Million | ₩1.24 Billion | ▲ +1269.7% |
| 2011 | 0.35x | ₩3.42 Billion | ₩1.20 Billion | — |